PALO ALTO, Calif., Jan. 11, 2016 /PRNewswire/ -- NuMedii, Inc. today announced the formation of a discovery collaboration with Astellas Pharma Inc. (“Astellas”) to identify new indications for a number of undisclosed Astellas compounds using NuMedii’s predictive Big Data intelligence technology.
“NuMedii’s predictive Big Data intelligence technology enables the discovery of new uses for both marketed drugs and shelved development assets across a number of therapeutic areas,” stated Asim Siddiqui, Ph.D., chief technology officer, NuMedii, Inc. “We are excited to partner with Astellas to explore new indications for a number of their assets which we hope will be of benefit to patients in need and the physicians who treat them.”
This is NuMedii’s second collaboration with a large pharmaceutical company in recent months. In September 2015, the Company announced a partnership with Allergan for discovery of new treatments for psoriasis.
The Company’s proprietary and dynamic Big Data intelligence technology consists of hundreds of millions of human, biological, pharmacological and clinical data points that NuMedii has normalized and annotated. NuMedii integrates these data with proprietary network-based algorithms to find both drug candidates and biomarkers predictive of efficacy for diseases. In 2013, NuMedii entered into a strategic technology partnership with the Intellectual Property and Life Science business of Thomson Reuters, creating an unprecedented repository of methodologies and content to systematically identify new applications for existing drug compounds. NuMedii is initially using its Big Data technology to discover and de-risk new indications for medicines.
Financial terms of the agreement were not disclosed.
About Astellas
Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at http://www.astellas.com.
About NuMedii, Inc.
NuMedii, Inc., discovers effective new drugs by translating its predictive data intelligence technology into therapies with a higher probability of therapeutic success. The Company’s exclusive Big Data technology, originally developed at Stanford University, utilizes large amounts of scientific data together with proprietary biological network-based algorithms to discover drug-disease connections and biomarkers that are predictive of efficacy. NuMedii translates these predictions into novel de-risked drug candidates and partners with pharmaceutical companies for development and commercialization. Headquartered in Palo Alto, California, NuMedii’s investors include Claremont Creek Ventures and Lightspeed Venture Partners. For more information, please visit www.numedii.com.
